Xelpros is a drug owned by Sun Pharmaceutical Industries Ltd. It is protected by 2 US drug patents filed in 2018 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Sep 12, 2029. Details of Xelpros's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US9629852 | Ophthalmic composition comprising a prostaglandin |
Sep, 2029
(4 years from now) | Active |
| US9539262 | Ophthalmic composition comprising a prostaglandin |
Oct, 2028
(3 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Xelpros's patents.
Latest Legal Activities on Xelpros's Patents
Given below is the list of recent legal activities going on the following patents of Xelpros.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 10 Jul, 2024 | US9539262 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 26 Oct, 2020 | US9629852 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 10 Jul, 2020 | US9539262 |
| Recordation of Patent Grant Mailed Critical | 25 Apr, 2017 | US9629852 |
| Patent Issue Date Used in PTA Calculation Critical | 25 Apr, 2017 | US9629852 |
| Email Notification Critical | 06 Apr, 2017 | US9629852 |
| Issue Notification Mailed Critical | 05 Apr, 2017 | US9629852 |
| Dispatch to FDC | 17 Mar, 2017 | US9629852 |
| Application Is Considered Ready for Issue Critical | 16 Mar, 2017 | US9629852 |
| Issue Fee Payment Verified Critical | 13 Mar, 2017 | US9629852 |
While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Xelpros and ongoing litigations to help you estimate the early arrival of Xelpros generic.
Xelpros's Litigations
Xelpros been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jun 06, 2013, against patent number US9629852. The petitioner , challenged the validity of this patent, with Ajay Jaysingh Khopade et al as the respondent. Click below to track the latest information on how companies are challenging Xelpros's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US9629852 | June, 2013 |
Decision
(26 Apr, 2016) | Ajay Jaysingh Khopade et al | |
US patents provide insights into the exclusivity only within the United States, but Xelpros is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Xelpros's family patents as well as insights into ongoing legal events on those patents.
Xelpros's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Xelpros's generic launch date based on the expiry of its last outstanding patent is estimated to be Sep 12, 2029 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Xelpros Generic API suppliers:
Latanoprost is the generic name for the brand Xelpros. 11 different companies have already filed for the generic of Xelpros, with Amring Pharms having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Xelpros's generic
Alternative Brands for Xelpros
Xelpros which is used for managing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension., has several other brand drugs using the same active ingredient (Latanoprost). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
Apart from brand drugs containing the same ingredient, some generics have also been filed for Latanoprost, Xelpros's active ingredient. Check the complete list of approved generic manufacturers for Xelpros
About Xelpros
Xelpros is a drug owned by Sun Pharmaceutical Industries Ltd. It is used for managing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Xelpros uses Latanoprost as an active ingredient. Xelpros was launched by Sun Pharm in 2018.
Approval Date:
Xelpros was approved by FDA for market use on 12 September, 2018.
Active Ingredient:
Xelpros uses Latanoprost as the active ingredient. Check out other Drugs and Companies using Latanoprost ingredient
Treatment:
Xelpros is used for managing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Dosage:
Xelpros is available in emulsion form for ophthalmic use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.005% | EMULSION | Discontinued | OPHTHALMIC |